Clinical trials: Incurable Disease
Cancer, Lung Cancer
PROStep: A Feasibility Trial Using PROs and Step Data to Monitor Patients With Lung and GI Cancers
Telemedicine allows clinicians to utilize modern telecommunication technology to provide healthcare services to patients including remote symptom monitoring.
- Conditions
- Cancer, Lung Cancer, Gastro-intestinal
- Trial name
- PROStep (NCT04616768)
- Testing
- PRO questionnaire, Step monitoring, Active nudge text feedback
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cancer, Neuralgia
Amitriptyline or Pregabalin to Treat Neuropathic Pain in Incurable Cancer
Rationale: Often, incurable cancer patients suffer from severe symptoms as (neuropathic) pain and fatigue with polypharmaceutic interventions as a consequence.
- Trial name
- Off-label (NCT00740571)
- Testing
- amitriptyline, pregabalin
- Where
- 2 sites in Netherlands
- Volunteers
- 130 people
- Sponsor
- Radboud University Medical Center
Malignant Melanoma
BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
This open-label, multicenter. single arm Phase I dose-escalation study with efficacy tail extension will evaluate the maximum tolerated dose/recommended dose, the safety and efficacy of vemurafenib (RO5185426) in pediatric…
- Trial name
- NCT01519323
- Testing
- vemurafenib
- Where
- 26 sites in United States, Australia and 8 more
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of enzalutamide alone and in combination with anastrozole, or exemestane, or fulvestrant in patients with incurable breast cancer.
- Trial name
- NCT01597193
- Testing
- enzalutamide, anastrozole, exemestane
- Where
- 17 sites in United States
- Volunteers
- 101 people
- Sponsor
- Pfizer
Adrenocortical Carcinoma
S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery
RATIONALE: Some tumors need growth factors produced by the body to keep growing. Suramin may interfere with the growth factor and stop the tumor from growing.
- Trial name
- NCT00002921
- Testing
- suramin, therapeutic hydrocortisone
- Where
- 65 sites in United States
- Volunteers
- 13 people
- Sponsor
- SWOG Cancer Research Network
Carcinoma, Non-small-cell Lung
OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
The purpose of this study is to determine if OSI-774 will improve overall survival of patients with incurable stage IIIB/IV non-small cell lung cancer compared to standard of care.
- Trial name
- NCT00036647
- Testing
- Tarceva (erlotinib HCl, OSI-774 )
- Where
- 97 sites in United States, Argentina and 15 more
- Volunteers
- 731 people
- Sponsor
- OSI Pharmaceuticals
Encephalopathy, Cerebral Palsy
Initiating Pediatric Palliative Care in ACT Group 4
Due to the wide range of diagnoses encountered in pediatric palliative care, the Association for Children's Palliative Care (ACT) and the Royal College of Paediatrics and Child Health (RCPCH) have developed a classification of…
- Conditions
- Encephalopathy, Cerebral Palsy, Cerebral Malformation, Traumatic Head Injury
- Trial name
- StartSPP (NCT06273267)
- Testing
- Collection of data from the patient's medical file
- Where
- France
- Volunteers
- 126 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Cancer, Colorectal Cancer
Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer
This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc.
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer
- Trial name
- CDX1307-02 (NCT00648102)
- Testing
- CDX-1307
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Celldex Therapeutics
GastroEsophageal Cancer, Incurable Disease
The Effect of exeRcise And Diet on Quality of Life in Patients With Incurable Cancer of Esophagus and Stomach (RADICES)
The survival of patients with incurable gastroesophageal cancer can extend over a year with anticancer therapy. However, the number of patients with deteriorating quality of life in this patient group steadily decreases over time…
- Trial name
- RADICES (NCT06138223)
- Testing
- Exercise intervention, Nutrition intervention
- Where
- 22 sites in Netherlands
- Volunteers
- 196 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Incurable Cancer Diseases, Other Incurable Diseases
Incurable Ill Patients Attitudes Towards Euthanasia and Assisted Suicide
Euthanasia and assisted dying are of growing interest for patients with incurable diseases. The possible methods are widely discussed by patient-societies, physicians, lawyers, theologians and philosophers.
- Trial name
- ESPIL (NCT00495482)
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Klinikum St. Georg gGmbH
Anxiety, Depression
Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies
This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started…
- Conditions
- Anxiety, Depression, Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT07336238
- Testing
- Psychotherapy, Psilocybin, Survey Administration
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Washington
Lung Cancer
PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer
RATIONALE: PF-00299804 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether PF-00299804 is more effective than a placebo in treating patients with advanced…
- Trial name
- NCT01000025
- Testing
- PF-00299804
- Where
- 89 sites in United States, Argentina and 10 more
- Volunteers
- 720 people
- Sponsor
- NCIC Clinical Trials Group
Non-Small Cell Lung Cancer
A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer
This randomized, Phase III, double-blind, placebo-controlled study will evaluate the safety and efficacy of MetMAb (onartuzumab) in combination with Tarceva (erlotinib) compared with treatment with Tarceva alone in patients with…
- Trial name
- NCT02031744
- Testing
- erlotinib [Tarceva], Onartuzumab [MetMAb]
- Where
- 8 sites in China
- Volunteers
- 530 people
- Sponsor
- Hoffmann-La Roche
Adult Central Nervous System Germ Cell Tumor, Adult Teratoma
Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors
This phase II trial studies how well palifosfamide works in treating patients with recurrent germ cell tumors. Drugs used in chemotherapy, such as palifosfamide, work in different ways to stop the growth of tumor cells, either by…
- Conditions
- Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Malignant Extragonadal Germ Cell Tumor, Malignant Extragonadal Non-Seminomatous Germ Cell Tumor
- Trial name
- NCT01808534
- Testing
- palifosfamide
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Indiana University
Colorectal Cancer, Lung Cancer
AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer
RATIONALE: AZD2171 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00343408
- Testing
- cediranib maleate, cisplatin, fluorouracil
- Where
- 3 sites in Canada
- Volunteers
- 31 people
- Sponsor
- NCIC Clinical Trials Group
Prostate Cancer
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
Current therapies for Stage III or Stage IV Prostate Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage III or…
- Trial name
- NCT00003516
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Burzynski Research Institute
Advanced Cancers
Sublingual Fentanyl for the Management of Breakthrough Pain
The goal of this clinical research study is to learn if an investigational dose of fentanyl sublingual spray (FSS) can help to control pain in patients with advanced cancer when given in an outpatient and inpatient setting.
- Trial name
- NCT02514252
- Testing
- Fentanyl Sublingual Spray (FSS), Questionnaires, Mental Ability Tests
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Kidney Cancer
Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Breast Cancer, Kidney Cancer, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00006126
- Testing
- busulfan, cyclophosphamide, etoposide
- Sponsor
- Northwestern University
Gastro-Esophageal Cancer
Cancer-associated Cachexia in Patients With Incurable Gastroesophageal Cancer
Patients with incurable gastroesophageal cancer are at high risk of cancer cachexia with an estimated prevalence of 60-80%. Cancer cachexia is defined as ongoing loss of skeletal muscle mass with or without loss of fat mass and…
- Trial name
- NCT06137508
- Where
- Denmark
- Volunteers
- 125 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx
Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
The goal of this clinical research study is to learn if utomilumab, when given with ISA101b, is able to shrink or slow the growth of tumors in patients with incurable HPV+ oropharyngeal squamous cell carcinoma.
- Conditions
- Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Oropharyngeal Cancer
- Trial name
- NCT03258008
- Testing
- Utomilumab, ISA101b
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center